FSD Pharma (NASDAQ:HUGE – Get Free Report) is scheduled to be releasing its earnings data on Friday, March 29th.
FSD Pharma Stock Performance
HUGE stock opened at $0.71 on Thursday. The firm has a market cap of $27.95 million, a PE ratio of -1.20 and a beta of 0.61. The firm’s 50 day moving average price is $0.83 and its 200-day moving average price is $1.00. FSD Pharma has a one year low of $0.65 and a one year high of $2.10.
Institutional Trading of FSD Pharma
An institutional investor recently raised its position in FSD Pharma stock. Renaissance Technologies LLC raised its position in FSD Pharma Inc. (NASDAQ:HUGE – Free Report) by 48.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 102,600 shares of the company’s stock after purchasing an additional 33,600 shares during the quarter. Renaissance Technologies LLC owned 0.26% of FSD Pharma worth $118,000 as of its most recent SEC filing. 1.24% of the stock is owned by hedge funds and other institutional investors.
FSD Pharma Company Profile
FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.
Further Reading
- Five stocks we like better than FSD Pharma
- How to Invest in Small Cap StocksĀ
- Best Bear Market Funds: Top 3 Investment Options to Consider
- How to invest in marijuana stocks in 7 stepsĀ
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Upcoming IPO Stock Lockup Period, Explained
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.